New drug cocktail aims to shrink Hard-to-Treat melanoma

NCT ID NCT04598009

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial is testing whether combining two drugs, binimetinib and imatinib, can shrink tumors in people with advanced KIT-mutant melanoma that cannot be removed by surgery. The study will enroll 25 participants with stage III or IV melanoma. The goal is to see how many patients respond to the treatment and to monitor side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
binimetinib and imatinib
What this could lead to
If it works, this combination could offer a new treatment option for people with advanced KIT-mutant melanoma that cannot be surgically removed.
What could go wrong
This is a small, early-phase trial with only 25 participants, so results may not apply to everyone. The drugs can cause side effects like nausea, fatigue, and skin issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA STAGE III are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • UC San Diego Moores Cancer Center

    RECRUITING

    La Jolla, California, 92093, United States

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.